Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.50 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.46 |
| ▸ | AHCY | P23526 | 1/20 | 0.46 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.45 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12482011 | 1.00 | ABCB1 (0.51) | ABCB1P2RX3P2RX4P2RX2GSK3A | |
| SCHEMBL20820186 | 0.91 | P2RX3 (0.51) | ABCB1P2RX3P2RX4P2RX2GSK3A | |
| SCHEMBL12247692 | 0.90 | LMNA (0.47) | ABCB1P2RX3P2RX4P2RX2GSK3A | |
| SCHEMBL13151614 | 0.87 | LMNA (0.45) | P2RX3P2RX4P2RX2ADORA2ALMNA | |
| SCHEMBL17706607 | 0.87 | P2RX3 (0.49) | ABCB1P2RX3P2RX4P2RX2GSK3A | |
| SCHEMBL24829628 | 0.85 | NT5E (0.44) | ABCB1ADORA2ALMNAP2RY11 | |
| SCHEMBL17453217 | 0.85 | NT5E (0.44) | ABCB1ADORA2ALMNAP2RY11 | |
| SCHEMBL930787 | 0.85 | NT5E (0.44) | ABCB1ADORA2ALMNAP2RY11 | |
| SCHEMBL19777955 | 0.85 | NT5E (0.44) | ABCB1ADORA2ALMNAP2RY11 | |
| SCHEMBL930786 | 0.85 | NT5E (0.44) | ABCB1ADORA2ALMNAP2RY11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210196741-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC | 2021-07-01 | — | — | US | disclosed |
| US-9585906-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2933260-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | Gilead Pharmasset LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150231166-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD SCIENCES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-9085573-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2015-07-21 | — | — | US | disclosed |
| US-8957046-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2015-02-17 | — | — | US | disclosed |
| US-8906880-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140315852-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140288020-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140187511-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-8735372-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140045783-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2014-02-13 | — | — | US | disclosed |
| US-8580765-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130029929-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-7964580-B2 | Nucleoside phosphoramidate prodrugs | PHARMASSET, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100016251-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2008121634-A2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016251-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ABCB1 1432/4885P2RX3 632/4885P2RX4 559/4885 |
| US-20140045783-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ABCB1 1475/4885P2RX3 622/4885P2RX4 554/4885 |
| US-20130029929-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ABCB1 1432/4885P2RX3 632/4885P2RX4 559/4885 |
| US-20140315852-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ABCB1 1432/4885P2RX3 632/4885P2RX4 559/4885 |
| US-20140187511-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ABCB1 1432/4885P2RX3 632/4885P2RX4 559/4885 |
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | PNP, NUDT1, TYMP | ABCB1 1432/4885P2RX3 632/4885P2RX4 559/4885 |
| US-20140288020-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ABCB1 1432/4885P2RX3 632/4885P2RX4 559/4885 |
| US-20150231166-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ABCB1 1432/4885P2RX3 632/4885P2RX4 559/4885 |
| US-20210196741-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ABCB1 1432/4885P2RX3 632/4885P2RX4 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.